Wnt Research AB (publ) announced that a poster on the previously communicated positive ad hoc observations from the ongoing clinical phase 2 study NeoFox, will be presented at ESMO Gastrointestinal Cancer Congress (ESMO GI), the leading European congress for gastrointestinal cancer held between June 26-29 in Munich, Germany. The poster presented at ESMO GI details ad hoc observations from 110 patients in the ongoing NeoFox study, indicating that a three-week pre-operative treatment with Foxy-5 rapidly reduces local tumour spread of colon cancer. Additionally, the poster includes new data on tumour (T)-staging.

NeoFox is an open, randomized phase 2 trial in patients with stage II/III colon cancer that compares pre-operative treatment withFoxy-5 to an untreated control group. The results in brief: Pre-operative treatment with FoxY-5 was associated with an excellent safety profile. Historicopathological examination of surgically removed tissue suggested an effect of Foxy-5 on the local spread of the primary tumors within 3-4 weeks of treatment: Fewer patients had perineural invasion of cancer cells; Fewer patients had venous invasion of cancer cells; Foxy-5 was associated with TN(M) downstaging.

The significance of histologic findings in a neoadjuvant setting in colon cancer is supported by an indirect comparison with neoadjuvant chemotherapy (FOLFOX). The title of the poster is: "Positive ad hoc results from neoadjuvant Foxy-5 treatment of colon cancer patients in the ongoing phase 2 NeoFox study." WntResearch has redesigned the study following the positive observations to focus on the early pre-operative effects in stage III colon cancer and plans to present initial efficacy data towards the year-end 2024. Final results are expected during secondH 2025.